Abstract
Amongst the most promising chemopreventive agents, certain natural polyphenols have recently received a great deal of attention from the scientific community, nutritionists, the pharmaceutical industry and the public, due to their demonstrated inhibitory activity against tumorigenesis. In view of their anticancer properties, these compounds also hold great promise as potential chemotherapeutic agents. However, to translate these chemopreventive agents into chemotherapeutic compounds, their exact mechanism of action must be delineated. The aim of this manuscript is to review recent findings suggesting that certain natural products bind and antagonize the anti-apoptotic effects of Bcl-2 family proteins such as Bcl-xL and Bcl-2. We will summarize recent studies that were aimed at the identification of the molecular targets of natural polyphenols and at the characterization of their mechanism of action on a molecular level. We will emphasize the importance of these findings that resides not only in the opportunity for the development of novel cancer treatments with these compounds, but also in the structural information that can be used for the design and development of novel and more effective semi-synthetic analogues. The finding reviewed here should encourage the study of possible direct effects of other dietary compounds on Bcl-2 family proteins.
Keywords: apoptosis, bcl-2, bcl-xl, polyphenols, gossypol, apogossypol, purpurogallin, catechins, theaflavins, chemoprevention
Current Pharmaceutical Design
Title: Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy
Volume: 10 Issue: 12
Author(s): Maurizio Pellecchia and John C. Reed
Affiliation:
Keywords: apoptosis, bcl-2, bcl-xl, polyphenols, gossypol, apogossypol, purpurogallin, catechins, theaflavins, chemoprevention
Abstract: Amongst the most promising chemopreventive agents, certain natural polyphenols have recently received a great deal of attention from the scientific community, nutritionists, the pharmaceutical industry and the public, due to their demonstrated inhibitory activity against tumorigenesis. In view of their anticancer properties, these compounds also hold great promise as potential chemotherapeutic agents. However, to translate these chemopreventive agents into chemotherapeutic compounds, their exact mechanism of action must be delineated. The aim of this manuscript is to review recent findings suggesting that certain natural products bind and antagonize the anti-apoptotic effects of Bcl-2 family proteins such as Bcl-xL and Bcl-2. We will summarize recent studies that were aimed at the identification of the molecular targets of natural polyphenols and at the characterization of their mechanism of action on a molecular level. We will emphasize the importance of these findings that resides not only in the opportunity for the development of novel cancer treatments with these compounds, but also in the structural information that can be used for the design and development of novel and more effective semi-synthetic analogues. The finding reviewed here should encourage the study of possible direct effects of other dietary compounds on Bcl-2 family proteins.
Export Options
About this article
Cite this article as:
Pellecchia Maurizio and Reed C. John, Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384880
DOI https://dx.doi.org/10.2174/1381612043384880 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research Case Report of a Large Rhinolith Cast – A Frequently Missed Diagnosis
New Emirates Medical Journal Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets MicroRNAs in the Intracellular Space, Regulation of Organelle Specific Pathways in Health and Disease
MicroRNA CT and MRI Features of Chondrosarcoma in the Mastoid Involving the Facial Nerve in Comparison to Facial Nerve Schwannoma
Current Medical Imaging Cellular Signaling in Cartilage Tissue Engineering
Current Signal Transduction Therapy State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery Current Status of Therapeutic Targeting of Developmental Signalling Pathways in Oncology
Current Pharmaceutical Biotechnology Detection of Early Cancer: Genetics or Immunology? Serum Autoantibody Profiles as Markers of Malignancy
Anti-Cancer Agents in Medicinal Chemistry Recent Applications of Artificial Intelligence in Early Cancer Detection
Current Medicinal Chemistry Understanding Mesenchymal Cancer: The Liposarcoma-Associated t(12;16) (q13;;p11) Chromosomal Translocation as a Model
Current Genomics Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Allelic Imbalances of the egfr Gene as Key Events in Breast Cancer Progression – the Concept of Committed Progenitor Cells
Current Cancer Drug Targets Diquaternized Curarelike Myorelaxants: Structure and Biological Activity
Mini-Reviews in Medicinal Chemistry Prepontine Chordoma Presenting with MRI Features of an Epidermoid Cyst: Case Presentation and a Mini-Review
Current Medical Imaging Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design